Our study found that dapagliflozin could decrease the serum levels of NLRP3, IL-1β, and IL-18 proteins in diabetic ApoE−/− mice and IL-1β level in nondiabetic ApoE−/− mice, indicating that the benefits of dapagliflozin in diabetic atherosclerosis may involve both the systematic and regional anti-inflammatory effects, perhaps by inhibition of NLRP3 inflammasome system. The gene discussed is IL1B; the disease is atherosclerosis.